New official's first major transaction: Incyte (INCY.US) plans to acquire Star for $20 billion, betting on potential blockbuster drugs for hemorrhagic diseases.

According to the Wisdom Financial APP, it has been learned from informed sources that as medium-sized pharmaceutical companies continue to seek acquisitions to strengthen their product lines, Incyte (INCY.US) is set to acquire private Star Therapeutics for up to $2 billion.